GYRE THERAPEUTICS, INC.
GYRECIK 0001124105 · Pharmaceutical Preparations · Nasdaq
- CATALYST BIOSCIENCES, INC. (until 2023-10-27)
- TARGACEPT INC (until 2015-08-19)
Revenue (TTM)
$101.91M
+10.2% YoY
Q1 May 2026
Net Income (TTM)
$1.39M
−44.8% YoY
Q1 May 2026
EPS Diluted (TTM)
−$0.07
−60.0% YoY
Q1 May 2026
Gross Margin
98.4%
Q1 May 2026
Operating Margin
2.0%
Q1 May 2026
Net Margin
1.4%
Q1 May 2026
Free Cash Flow (TTM)
$14.08M
Q1 May 2026
Cash
$37.5M
Q1 May 2026
Total Debt
$620K
Q1 May 2026
Shares Outstanding
97.03M sh
Q1 May 2026